Entrectinib

Definition

An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.

NCIT:C114984 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as ENTRECTINIB, N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide, Rozlytrek, RXDX 101, RXDX-101, RXDX101 — per NCIT

Also identified as

ATC L01EX14 per RXNORM
NCIT NCIT:C114984 per NCIT
SCTID 789356007 per RXNORM
SCTID 789364001 per RXNORM
UNII L5ORF0AN1I per RXNORM

Indications

Disease	Relation	Source
Non-small cell lung carcinoma	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Lungs	may treat a disease of this organ	DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.